Abstract
We present results obtained in five patients with advanced thyroid cancer, derived from the follicular epithelium, treated with Sorafenib used off-label. The median age at the time Sorafenib was started was 61 years. Only one patient tolerated the standard dose of 400 mg twice daily. The most severe adverse events were:.
Original language | English |
---|---|
Pages (from-to) | 1084-1087 |
Number of pages | 4 |
Journal | Journal of cancer research and therapeutics |
Volume | 12 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2016 |
Keywords
- I-131 refractory
- kinase inhibitor
- Sorafenib
- thyroid carcinoma
- PHASE-II TRIAL
- DOUBLE-BLIND
- CANCER
- PAPILLARY
- EFFICACY